Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapiesDrugs in Context, 2020
- Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti‐PD‐1 inhibitorInternational Journal of Cancer, 2018
- Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusionPLOS ONE, 2018
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung CancerJAMA Oncology, 2018
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapyCancer Immunology, Immunotherapy, 2012
- Cancer‐promoting tumor‐associated macrophages: New vistas and open questionsEuropean Journal of Immunology, 2011
- CD4+CD25− T Cells That Express Latency-Associated Peptide on the Surface Suppress CD4+CD45RBhigh-Induced Colitis by a TGF-β-Dependent MechanismThe Journal of Immunology, 2003
- Role for IL-10 in Suppression Mediated by Peptide-Induced Regulatory T Cells In VivoThe Journal of Immunology, 2003
- Chemokines: a superfamily of chemotactic cytokinesInternational Journal of Clinical and Laboratory Research, 1996